Request Deal Involvement

Bristol-Myers Squibb completed the acquisition of MyoKardia for $13.1bn.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

W2O Group

pr advisors

W2O Group

Centerview Partners

financial advisors

Centerview Partners

Goodwin Procter

legal advisors

Goodwin Procter

Sullivan & Cromwell

legal advisors to financial advisors

Sullivan & Cromwell

Precision AQ

pr advisors

Precision AQ

Guggenheim Partners

financial advisors

Guggenheim Partners

Gordon Dyal & Co

financial advisors

Gordon Dyal & Co

Guggenheim Partners

financial advisors

Guggenheim Partners

Kirkland & Ellis

legal advisors

Kirkland & Ellis

Joele Frank

pr advisors

Joele Frank

Davis Polk & Wardwell

legal advisors to financial advisors

Davis Polk & Wardwell

or

Principals

MYOKARDIA

target

MYOKARDIA

BRISTOL MYERS SQUIBB COMPANY

bidder

BRISTOL MYERS SQUIBB COMPANY

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Bristol-Myers Squibb completed the acquisition of MyoKardia for $13.1bn.